Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Active not recruiting 23Recruiting 12Completed 9Terminated 8Not yet recruiting 5Withdrawn 2Available 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 4Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

Dexamethasone 20daratumumab 17Bortezomib 12Lenalidomide 11pomalidomide 8Cyclophosphamide 8Calcium Dobesilate 7belantamab mafodotin 5isatuximab 4fludarabine 4carfilzomib 4Melphalan 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3Biopsy 3tocilizumab 2iberdomide 2Stem Cell Transplantation 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Hyaluronoglucosaminidase 2Fluorodeoxyglucose F18 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2zanubrutinib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × belantamab mafodotin × Plasma cell × Clear all
NCT07614360 2026-05-29

DREAMM-16

GlaxoSmithKline

Phase 2 Not yet recruiting
120 enrolled
Plasma cell

Multiple Myeloma

NCT07609706 2026-05-27

A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

GlaxoSmithKline

Phase 1 Not yet recruiting
20 enrolled
Plasma cell

Multiple Myeloma

NCT07285239 2026-05-18

PrE1005

PrECOG, LLC.

Phase 3 Not yet recruiting
500 enrolled
Plasma cell

Multiple Myeloma

NCT07224672 2026-03-17

ALANIS

GlaxoSmithKline

Phase 2 Not yet recruiting
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT05874193 2026-02-05

COSTA

Duke University

Phase 2 Not yet recruiting
33 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡